Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547000 · ClinicalTrials.gov registry record · Phase 4
Guanfacine in Children With Tic Disorders
A Phase 4 study of Tourette Syndrome and Tourette Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 3
- Study locations
NCT01547000 is a Phase 4 study of Tourette Syndrome and Tourette Disorder that has completed, run by Yale University. The registered enrollment target is 34 participants, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (60% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01547000, a Phase 4 study of Tourette Syndrome and Tourette Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this pilot study is to obtain preliminary information on the tolerability and efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette Disorder (TD, also called Tourette syndrome).
Conditions Studied
Interventions
- DRUG placebo
- DRUG extended-release guanfacine (Intuniv)
Study Locations (3)
Connecticut
- Yale Child Study Center - New Haven
Florida
- University of South Florida - Tampa
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01547000
The ClinicalTrials.gov registry entry for NCT01547000 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (60% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tourette Syndrome appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01547000 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01547000 about?
NCT01547000 is a clinical study titled "Guanfacine in Children With Tic Disorders". The goal of this pilot study is to obtain preliminary information on the tolerability and efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette Disorder (TD, also called Tourette syndrome).
What is the current status of trial NCT01547000?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2012-04. Estimated completion is 2016-12.
What conditions does trial NCT01547000 study?
This clinical trial studies the following conditions: Tourette Syndrome, Tourette Disorder.
What interventions are being tested in trial NCT01547000?
The interventions under investigation include: placebo (DRUG), extended-release guanfacine (Intuniv) (DRUG).
Who is sponsoring clinical trial NCT01547000?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01547000 being conducted?
This trial has 3 study locations across Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
COMPLETED · Phase 4
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Sensory Symptoms in Tourette Syndrome
RECRUITING
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.